EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Erdosteine Provides Effective Analgesia in Inflammatory Pain Without Impairing Pain Resolution: A Preclinical Comparison With Non‐Steroidal Anti‐Inflammatory Drugs

Lucas Vasconcelos Lima iD, Mohamad Karaky, Grace Yu, Massimo Allegri, Nicoletta Marchesi, Stefano Govoni, Clive Page, Luda Diatchenko

European Journal of Pain · 2026

DOI: 10.1002/ejp.70334 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Pain, 2026. Verfasst von Lucas Vasconcelos Lima und 7 weiteren Autor:innen. Beteiligte Einrichtung: Alan Edwards Centre for Research on Pain, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Thioglycolates, Anti-Inflammatory Agents, Non-Steroidal, Inflammation, Thiophenes. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nonsteroidal anti‐inflammatory drugs (NSAIDs) provide effective analgesia but may paradoxically delay tissue recovery, pain resolution and contribute to chronic pain. Erdosteine, a thiol‐based prodrug with antioxidant and anti‐inflammatory properties, is a mucolytic used for treatment of respiratory diseases but has recently been suggested to possess analgesic potential.

Methods

We examined the analgesic efficacy of erdosteine and its metabolite, Met‐1, in experimental models of inflammatory and neuropathic pain and compared its effects with diclofenac and gabapentin. Male mice received complete Freund's adjuvant (CFA) or chronic constriction injury (CCI) to induce inflammatory or neuropathic pain, respectively. Erdosteine (100 or 300 mg/kg, per os), its metabolite MET‐1 (intravenous), diclofenac (per os), gabapentin (per os), or vehicle (per os or intravenous as appropriate) were administered for 7 days following CFA or CCI. In separate experiments, treatments were initiated prior to CFA. Mechanical allodynia was quantified by von Frey testing. Plasma levels of CXCL1, S100A8/S100A9, IL‐1Ra, and 8‐isoprostane were measured by ELISA.

Results

Erdosteine significantly reduced CFA‐induced allodynia, with efficacy comparable to diclofenac and gabapentin. Unlike diclofenac, erdosteine did not delay pain recovery in post‐CFA or pre‐CFA experimental settings and did not elevate plasma CXCL1 or 8‐isoprostane levels.

Conclusions

Erdosteine provides robust analgesia in an experimental model of inflammatory pain without disrupting inflammation‐resolution pathways or increasing oxidative stress, supporting its potential as a safe, non‐opioid analgesic. These findings support further investigation of erdosteine as a potential, non‐opioid analgesic drug that does not produce the adverse events associated with NSAIDs. Perspective Erdosteine produced NSAID‐comparable analgesia in inflammatory pain without delaying recovery or increasing oxidative and inflammatory markers. Given concerns that NSAIDs may prolong pain resolution, these findings identify erdosteine as a potential non‐opioid alternative that relieves inflammatory pain while preserving physiological healing processes. Significance Statement Effective and well‐tolerated treatments for chronic pain remain limited. Erdosteine is a clinically approved mucolytic with antioxidant and anti‐inflammatory properties whose analgesic potential is largely unexplored. We show that oral erdosteine reduces inflammatory pain and allodynia without delaying recovery, unlike the NSAID diclofenac, which increased systemic markers of inflammation and prolonged pain duration. These findings identify erdosteine as a promising candidate for drug repurposing and support further investigation of its potential utility in pain management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThioglycolatesAnti-Inflammatory Agents, Non-SteroidalInflammationThiophenesAnalgesicsNeuralgiaPainExpectorantsAnimalsMaleMiceHyperalgesiaDiclofenacFreund's AdjuvantGabapentinDisease Models, Animal

Stichwörter der Autor:innen

ErdosteineNSAIDsdrug repurposingoxidative stresspain resolution

Substanzen

ThioglycolateserdosteineAnti-Inflammatory Agents, Non-SteroidalThiophenesDiclofenacAnalgesicsFreund's AdjuvantGabapentinExpectorants

Autor:innen und Institutionen

  • Alan Edwards Centre for Research on Pain, McGill University, Montreal, Quebec, Canada.
  • Department of Anesthesia, Faculty of Dentistry, McGill University, Montreal, Quebec, Canada.
  • Centre Lémanique de Neuromodulation et Thérapie de la Douleur, Ensemble Hospitalier de la Côte, Morges, Switzerland.
  • Department of Drug Sciences, University of Pavia, Pavia, Italy.
  • Institute of Pharmaceutical Science, King's College London, London, UK.

ORCID-Profile: Lucas Vasconcelos Lima

Zitieren

APA

Vasconcelos Lima, L., Karaky, M., Yu, G., Allegri, M., Marchesi, N., Govoni, S., Page, C., & Diatchenko, L. (2026). Erdosteine Provides Effective Analgesia in Inflammatory Pain Without Impairing Pain Resolution: A Preclinical Comparison With Non‐Steroidal Anti‐Inflammatory Drugs. European Journal of Pain. https://doi.org/10.1002/ejp.70334

Vancouver

Vasconcelos Lima L, Karaky M, Yu G, Allegri M, Marchesi N, Govoni S, et al. Erdosteine Provides Effective Analgesia in Inflammatory Pain Without Impairing Pain Resolution: A Preclinical Comparison With Non‐Steroidal Anti‐Inflammatory Drugs. European Journal of Pain. 2026. doi:10.1002/ejp.70334

BibTeX
@article{VasconcelosLima2026,
  author = {Vasconcelos Lima, Lucas and Karaky, Mohamad and Yu, Grace and Allegri, Massimo and Marchesi, Nicoletta and Govoni, Stefano and Page, Clive and Diatchenko, Luda},
  title = {Erdosteine Provides Effective Analgesia in Inflammatory Pain Without Impairing Pain Resolution: A Preclinical Comparison With Non‐Steroidal Anti‐Inflammatory Drugs},
  journal = {European Journal of Pain},
  year = {2026},
  doi = {10.1002/ejp.70334}
}
Kostenlos starten →